COMBINATION THERAPY FOR THE TREATMENT OF KRAS-MUTANT PANCREATIC CANCER: PRE-CLINICAL INVESTIGATION OF THE NOVEL INHIBITORS RMC-4550 (SHP2I) AND LY3214996 (ERKI)

Katrin Jana Frank  ¹     Antonio Mulero-Sánchez  ²     Alexandra Berninger  ²     Laura Ruiz-Cañas  ^{3, 4}     Astrid Bosma  ⁴     Kivanc Görgülü  ⁴     Nan Wu  ⁴     Nina Diakopoulos  ⁴     Ezgi Kaya-Aksoy  ⁴     Dietrich Alexander Ruess  ⁵     Derya Kabacaoglu  ⁵     Fränze Schmidt  ⁵     Larissa Kohlmann  ⁵     Olaf van Tellingen  ⁵     Bram Thijssen  ⁵     Marieke van de Ven  ⁵     Natalie Proost  ⁵     Susanne Kossatz  ^{1, 1}     Wolfgang A. Weber  ¹     Bruno Sainz, Jr  ^{3, 4}     René Bernards  ⁴     Hana Algül  ⁴     Marina Lesina  ⁴     Sara Mainardi  ^4    
1 Technische Universität München, München, Germany
² The Netherlands Cancer Institute, Amsterdam, Netherlands
³ Universidad Autónoma de Madrid (UAM) and Instituto de Investigaciones Biomédicas "Alberto Sols" (IIBM), Madrid, Spain
⁴ Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain
⁵ Medical Center University of Freiburg, Freiburg, Germany

Topic
Digestive Oncology, Hepatobiliary, Histopathology, Pancreas

Session
Molecular and transitional aspects of PDHC

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)